TP53 mutations and the association with platinum resistance in high grade serous ovarian carcinoma

CONCLUSIONS: TP53 hotspot mutations or high pathogenicity scores were not associated with platinum resistance or refractory disease. Contrary to prior studies, TP53 gain-of-function mutations were not associated with platinum resistance. Estimation of TP53 gain-of-function effect using missense mutation phenotype scores was not associated with platinum resistance. The polymorphic nature of TP53 mutations may be too complex to demonstrate effect using simple models, or response to platinum therapy may be independent of initiating TP53 mutation.PMID:38555766 | DOI:10.1016/j.ygyno.2024.03.023

Source: Gynecologic Oncology - March 31, 2024 Category: Cancer & Oncology Authors: Lauren Montemorano Zoey B Shultz Alma Farooque Meredith Hyun Richard J Chappell Ellen M Hartenbach Jessica D Lang Source Type: research